Harvard Bioscience (HBIO) Scheduled to Post Earnings on Thursday

Harvard Bioscience (NASDAQ:HBIO) is scheduled to be releasing its earnings data before the market opens on Thursday, November 7th. Analysts expect Harvard Bioscience to post earnings of $0.05 per share for the quarter. Harvard Bioscience has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.06). Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%. The company had revenue of $23.10 million for the quarter, compared to the consensus estimate of $29.91 million.

Harvard Bioscience Price Performance

NASDAQ:HBIO opened at $2.39 on Wednesday. The company has a market cap of $104.23 million, a P/E ratio of -9.56 and a beta of 1.31. The firm’s fifty day moving average price is $2.59 and its two-hundred day moving average price is $2.96. Harvard Bioscience has a one year low of $2.30 and a one year high of $5.56. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.05 and a quick ratio of 0.94.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.